DPP4 and type 2 diabetes mellitus: Clinically, Rizzo et al. demonstrated that MAGE reduction achieved with dipeptidyl peptidase-IV inhibitors is associated with reduction of oxidative stress and markers of systemic inflammation in T2DM [21].